[1] Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 2010; 31, 2844-53. doi:  10.1093/eurheartj/ehq386
[2] Imhof A, Rothenbacher D, Khuseyinova N, et al. Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease. Eur J Cardiovasc Prev Rehabil, 2003; 10, 362-70. doi:  10.1097/01.hjr.0000087080.83314.be
[3] Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science, 1993; 260, 1655-8. doi:  10.1126/science.8503012
[4] Krychtiuk KA, Kastl SP, Hofbauer SL, et al. Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a). J Clin Lipidol, 2015; 9, 533-41. doi:  10.1016/j.jacl.2015.04.005
[5] Kamstrup PR, Benn M, Tybjaerg-Hansen A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation, 2008; 117, 176-84. doi:  10.1161/CIRCULATIONAHA.107.715698
[6] Nsaibia MJ, Mahmut A, Boulanger MC, et al. Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease. J Intern Med, 2016; 280, 509-17. doi:  10.1111/joim.2016.280.issue-5
[7] Nave AH, Lange KS, Leonards CO, et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis, 2015; 242, 496-503. https://www.sciencedirect.com/science/article/pii/S0021915015300848
[8] Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med, 2009; 361, 2518-28. doi:  10.1056/NEJMoa0902604
[9] A joint committee on guidelines of the prevention and control of adult dyslipidemia in China. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Chin J Cardiol, 2007; 35, 390-419. (In Chinese)
[10] Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016; 37, 2999-3058. doi:  10.1093/eurheartj/ehw272
[11] Bjornsson E, Gudbjartsson DF, Helgadottir A, et al. Common sequence variants associated with coronary artery disease correlate with the extent of coronary atherosclerosis. Arterioscler Thromb Vasc Biol, 2015; 35, 1526-31. doi:  10.1161/ATVBAHA.114.304985
[12] Brown WV, Ballantyne CM, Jones PH, et al. Management of Lp(a). J Clin Lipidol, 2010; 4, 240-7. doi:  10.1016/j.jacl.2010.07.002
[13] Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation, 2014; 129, 635-42. doi:  10.1161/CIRCULATIONAHA.113.004406
[14] Li S, Wu NQ, Zhu CG, et al. Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis, 2017; 260, 67-74. doi:  10.1016/j.atherosclerosis.2017.03.021
[15] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983; 51, 606. doi:  10.1016/S0002-9149(83)80105-2
[16] Hopewell JC, Seedorf U, Farrall M, et al. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med, 2014; 276, 260-8. doi:  10.1111/joim.12187
[17] Schwartzman RA, Cox ID, Poloniecki J, et al. Elevated plasma lipoprotein(a) is associated with coronary artery disease in patients with chronic stable angina pectoris. J Am Coll Cardiol, 1998; 31, 1260-6. doi:  10.1016/S0735-1097(98)00096-5
[18] Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 2009; 302, 412-23. doi:  10.1001/jama.2009.1063
[19] Cai DP, He YM, Yang XJ, et al. Lipoprotein (a) is a risk factor for coronary artery disease in Chinese Han ethnic population modified by some traditional risk factors: A cross-sectional study of 3462 cases and 6125 controls. Clin Chim Acta, 2015; 451, 278-86. doi:  10.1016/j.cca.2015.10.009
[20] Wang L, Chen J, Zeng Y, et al. Functional Variant in the SLC22A3-LPAL2-LPA Gene Cluster Contributes to the Severity of Coronary Artery Disease. Arterioscler Thromb Vasc Biol, 2016; 36, 1989-96. doi:  10.1161/ATVBAHA.116.307311
[21] Zewinger S, Kleber ME, Tragante V, et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol, 2017; 5, 534-43. doi:  10.1016/S2213-8587(17)30096-7
[22] O'Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol, 2014; 63, 520-7. doi:  10.1016/j.jacc.2013.09.042
[23] Boroumand MA, Rekabi V, Davoodi G, et al. Correlation between lipoprotein(a) serum concentration and severity of coronary artery stenosis in an Iranian population according to Gensini score. Clin Biochem, 2008; 41, 117-20. doi:  10.1016/j.clinbiochem.2007.10.004
[24] Moon JY, Kwon HM, Kwon SW, et al. Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology, 2007; 108, 282-9. doi:  10.1159/000099097
[25] Gazzaruso C, Bruno R, Pujia A, et al. Lipoprotein(a), apolipoprotein(a) polymorphism and coronary atherosclerosis severity in type 2 diabetic patients. Int J Cardiol, 2006; 108, 354-8. doi:  10.1016/j.ijcard.2005.05.022
[26] Kral BG, Kalyani RR, Yanek LR, et al. Relation of Plasma Lipoprotein(a) to Subclinical Coronary Plaque Volumes, Three-Vessel and Left Main Coronary Disease, and Severe Coronary Stenoses in Apparently Healthy African-Americans With a Family History of Early-Onset Coronary Artery Disease. Am J Cardiol, 2016; 118, 656-61. doi:  10.1016/j.amjcard.2016.06.020
[27] Sinning C, Lillpopp L, Appelbaum S, et al. Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clin Res Cardiol, 2013; 102, 495-503. doi:  10.1007/s00392-013-0555-4
[28] Afshar M, Pilote L, Dufresne L, et al. Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS). J Am Heart Assoc, 2016; 5. http://cn.bing.com/academic/profile?id=6619ab5ae6d7037d789a27b24f1e68e7&encoded=0&v=paper_preview&mkt=zh-cn
[29] Cai A, Li L, Zhang Y, et al. Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement. Dis Markers, 2013; 35, 857-62. doi:  10.1155/2013/472845
[30] Saeedi R, Li M, Allard M, et al. Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol. Clin Biochem, 2014; 47, 1098-9. doi:  10.1016/j.clinbiochem.2014.04.023
[31] Tsimikas S. The re-emergence of lipoprotein(a) in a broader clinical arena. Prog Cardiovasc Dis, 2016; 59, 135-44. doi:  10.1016/j.pcad.2016.07.005
[32] Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1, 300 patients in 4 phase Ⅱ trials. J Am Coll Cardiol, 2014; 63, 1278-88. doi:  10.1016/j.jacc.2014.01.006
[33] Roeseler E, Julius U, Heigl F, et al. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Arterioscler Thromb Vasc Biol, 2016; 36, 2019-27. doi:  10.1161/ATVBAHA.116.307983